ArticleRenal failure2025
Urinary long non-coding RNA GAS5 as a noninvasive diagnostic biomarker for renal fibrosis.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Pharmacological targeting of kidney fibrosis: druggable mechanisms, translational models, and emerging antifibrotic therapies.Clinical kidney journal · 2026Review
- Can urinary exosomal lncRNAs HOTAIR and MALAT1 predict surgical need and outcomes in unilateral antenatal hydronephrosis?Pediatric surgery international · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal fibrosis, the terminal pathological pathway of chronic kidney disease (CKD), lacks reliable noninvasive biomarkers for clinical assessment. Current diagnostic reliance on renal biopsy-despite its gold-standard status-poses risks of bleeding and sampling errors, necessitating alternatives. Long non-coding RNA growth arrest-specific 5 (GAS5) regulates fibrogenic pathways, but its utility as a liquid biopsy marker remains unexplored.
methodThis prospective cross-sectional study quantified GAS5 levels in paired plasma and urine samples from 198 CKD patients (stratified by renal fibrosis scoring: mild: <25%, moderate: 25-50%, severe: ≥50% fibrotic area) and 20 healthy controls. Multivariate regression models adjusted for cardiorenal confounders (hypertension, blood pressure, and so on) evaluated GAS5's association with fibrosis.
resultsPlasma GAS5 levels increased with renal fibrosis severity, whereas urinary GAS5 exhibited progressive suppression. After adjusting for factors such as hypertension history, systolic and diastolic blood pressure, blood urea nitrogen, creatinine, eGFR, and uric acid, use of ACEI/ARB, multivariate analysis showed significant associations between urinary GAS5 level and renal fibrosis. ROC analysis revealed urinary GAS5's superior diagnostic accuracy compared with eGFR and TGF-β1. AUCs of urinary GAS5 were even higher in moderate and severe renal fibrosis group.
conclusionsWhile plasma GAS5 upregulation and urinary GAS5 suppression reflect inverse expression patterns in renal fibrosis, urinary GAS5 emerges as the dominant noninvasive biomarker due to its superior diagnostic performance (AUC = 0.868) and clinical accessibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.